相关临床试验
16
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1889
已完成
7
43.8%
Enrolling By Invitation
1
6.3%
尚未招募
2
12.5%
招募中
4
25.0%
Unknown
2
12.5%
暂无批准数据
- Bracco Imaging is leveraging its 25-year-old microbubble platform to develop a bead-free alternative for cell selection and activation in cell therapy manufacturing. - The technology uses buoyancy-based cell selection that reduces cellular stress compared to magnetic bead methods and leaves no residual materials in processed cells. - Bracco plans to begin GMP-compliant manufacturing at its Geneva facility in 2027, targeting partnerships with cell therapy developers and offering evaluation kits for early-access partners. - The platform supports both positive and negative selection strategies and aims to enable isolation of harder-to-purify immune cell subsets beyond standard CD3+ T-cell workflows.
- A groundbreaking study of nearly 3,500 cancer patients revealed that thymic health, assessed through AI analysis of routine chest CT scans, significantly predicts immunotherapy response across multiple cancer types. - Patients with higher thymic health scores showed a 35% lower risk of cancer progression and 44% lower risk of death when treated with immune checkpoint inhibitors. - The findings suggest thymic health could serve as a non-invasive, tumor-agnostic biomarker to enhance patient stratification in precision oncology, addressing current limitations of existing biomarkers. - Validation studies using T-cell receptor sequencing confirmed that thymic health correlates with immune competence, representing a missing pillar in current cancer biomarker panels.
